Filing Flows › Ensysce Biosciences (ENSC) › Q1 2026 › vs Q4 2025
Ensysce Biosciences (ENSC) Q1 2026 vs Q4 2025 (quarter over quarter)
Ensysce Biosciences's revenue fell $921K (-49%) from $1.9M in Q4 2025 to $961K in Q1 2026.
Ensysce Biosciences, Q1 2026: revenue $961K (-27% year over year), operating margin -370.7%, net loss $3.6M, operating cash flow −$3.5M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $961K | $1.9M | −$921K | -49% |
| Other income, net | $6K | $14K | −$8K | -58% |
| Net loss | $3.6M | $2.8M | $788K | +28% |
| Costs & expenses | $4.5M | $4.7M | −$141K | -3% |
| Operating costs | $4.5M | $4.7M | −$141K | -3% |
| Research & development | $3.3M | $3.6M | −$266K | -7% |
| General & admin | $1.2M | $1.1M | $125K | +12% |
| Operating cash sources | $3.6M | $2.8M | $788K | +28% |
| Depreciation | $7K | $7K | $0 | 0% |
| Share-based compensation | $9K | $24K | −$16K | -64% |
| Working capital & other | $40K | $1.2M | −$1.2M | -97% |
| Cash used in operations | $3.5M | $1.5M | $2.0M | +129% |
| Net loss absorbed | $3.6M | $2.8M | $788K | +28% |
Questions
How much did Ensysce Biosciences's revenue grow quarter over quarter in Q1 2026?
Ensysce Biosciences's revenue fell $921K (-49%) from $1.9M in Q4 2025 to $961K in Q1 2026.